Form 4: Glaukos Corp Director David F. Hoffmeister Reports Stock and Option Grant

Director David F. Hoffmeister reports the acquisition of restricted stock units and stock options in Glaukos Corporation.

Summary

• On May 30, 2024, David F. Hoffmeister, a director of Glaukos Corporation, reported transactions involving the company's stock.
• Hoffmeister acquired 1,716 shares of common stock through a grant of restricted stock units, which will vest on the one-year anniversary of the grant date.
• He also acquired a stock option to buy 1,246 shares of common stock, vesting in full on the one-year anniversary of the grant date and expiring on May 30, 2034.
• Following these transactions, Hoffmeister directly owns 7,483 shares of common stock and indirectly owns 34,946 shares through Sentinel Point Partners, Inc.
• The indirect ownership includes 6,028 restricted stock units that have not yet vested or delivery of which has been deferred.
• A transfer of 10,000 shares from direct ownership to a corporation where Hoffmeister is the sole stockholder did not change his beneficial ownership.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports routine insider transactions related to director compensation. There are no indications of significant positive or negative events.

Positives

• The grant of restricted stock units and stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Future Outlook

The restricted stock units will vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. The stock options vest in full on the one-year anniversary of the grant date.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. These transactions are part of standard director compensation packages.

Comparison to Industry Standards

• Director compensation packages often include a mix of cash, stock options, and restricted stock units.
• The vesting schedules and terms of these grants are generally in line with industry practices for companies of similar size and stage.
• Comparing Glaukos' director compensation to companies like Aerie Pharmaceuticals (acquired by Alcon) or Iridex Corporation, which also operate in the ophthalmic space, would provide a relevant benchmark.

Stakeholder Impact

• The transactions have a minor positive impact on shareholders as they align the director's interests with the company's long-term performance.

Key Dates